MOTS-c

MOTS-c (also known as Mitochondrial ORF of 12S rRNA Type-c) is a prominently researched experimental compound classified strictly within the Mitochondrial Peptide framework. Operating primarily through advanced pharmacological pathways, its core mechanism of action is as follows: it regulates mitochondrial function and AMPK. Enhances glucose uptake and fatty acid oxidation, improves insulin sensitivity, and protects against age-related metabolic decline. with a documented biological half-life of roughly 4 hours, In preclinical investigative trials and independent academic studies, researchers utilizing MOTS-c have documented significant, quantifiable biological outcomes, primarily focusing on energy, metabolism, fat loss, longevity. Typical research protocols investigate administering 2000 to 2000mcg via subq pathways 5x/week. However, it is critically important to understand that while MOTS-c demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.